BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, June 4, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 7, 2014
View Archived Issues
Shionogi updates developments of third quarter of fiscal 2013
Read More
Roche reviews recent highlights of fourth quarter 2013
Read More
Discovery of a novel IAP antagonist with clinical potential for the treatment of cancer
Read More
Swiss group presents novel agents for cancer and other disorders
Read More
MacroGenics achieves milestone under agreement with Servier for MGD-006
Read More
Janssen Pharmaceutica synthesizes new CCR2 receptor antagonists
Read More
Merck & Co. collaborates with Amgen, Incyte and Pfizer to study new anticancer regimens
Read More
Second-generation proteasome inhibitors could be repurposed as antivirals
Read More
Novo Nordisk returns full rights for IPH-2201 to Innate Pharma
Read More
Researchers detail design of MPS1 inhibitor CCT-251455
Read More
Researchers report novel method of somatic cell reprogramming into bidirectional pluripotent cells
Read More
TG-01 enters phase IIa trial in operable pancreatic cancer
Read More
Audentes and Genethon enter agreement to develop gene therapy for X-linked myotubular myopathy
Read More
Novartis patents novel complement factor D inhibitors
Read More
Scientists at Euclises Pharmaceuticals disclose novel antitumor agents
Read More
Infectex acquires exclusive rights to Qurient's tuberculosis drug
Read More
Argos Therapeutics presents update on the phase III ADAPT trial evaluating AGS-003
Read More
Navidea reports initial results from phase IIb trial of its beta-amyloid imaging agent NAV-4694
Read More
Shire decides to discontinue development of Vyvanse capsules for major depressive disorder
Read More
ProMetic enters new development agreement with vaccines company
Read More
REGiMMUNE initiates phase II trial of RGI-2001 for graft versus host disease
Read More
FDA accepts NDA filing for Beleodaq
Read More
Trigemina expands phase II study of intranasal oxytocin candidate for chronic migraine
Read More
Roche reports development of novel cell penetrating peptides for cancer
Read More
